News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
HIV treatment for children and young people
Why has the uptake of lopinavir/ritonavir oral pellets for children been slow?

Lopinavir/ritonavir (LPV/r) oral pellets and oral granules for infants and young children living with HIV have proven advantages in terms of efficacy and tolerability over other formulations of

Published
02 May 2019
By
Carole Leach-Lemens
PrEP policies and guidelines
Gilead: Stop Blocking PrEP

Members of ACT UP Dublin gathered outside the High Court in Dublin this morning as Gilead’s legal team arrived for the first day of a trial on the validity of the Supplementary Protection Certificate (SPC) for Truvada. The original patent expired in 2017, but the disputed SPC would extend Gilead’s monopoly on Truvada until 2020 in Ireland.

Published
01 May 2019
From
Act Up Dublin
Elimination of hepatitis C
NHS trumpets Hep C deal, quietly drops 2025 elimination target after legal row

NHS England has announced a deal with AbbVie, Gilead, and Merck, Sharpe and Dohme (MSD) that aims to eliminate hepatitis C from the country – although it has had to drop a 2025 target date because of a legal row during the procurement process.

Published
30 April 2019
From
pharmaphorum
Elimination of hepatitis C
NHS England strikes world leading deal to help eliminate hepatitis C

The NHS will find and cure tens of thousands more people with hepatitis C as part of a ground-breaking deal that could help England become the first country in the world to eliminate the deadly virus.

Published
30 April 2019
From
NHS England
Long-acting HIV treatment
ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine

If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV

Published
29 April 2019
From
ViiV press release
New and experimental HIV treatments
ViiV Healthcare announces CHMP Positive Opinion for Dovato® (dolutegravir/lamivudine) as a once-daily, single-pill, two-drug regimen for the treatment of HIV infection

Recommendation based on landmark GEMINI 1 & 2 studies which demonstrated non-inferior efficacy of dolutegravir + lamivudine compared to a traditional dolutegravir-based, three-drug regimen, in HIV-1 infected, treatment-naïve adults.

Published
26 April 2019
From
ViiV press release
Activism
How Activists Uncovered CDC's Ownership of Truvada PrEP Patents

"Nothing for us without us!" When PrEP4All co-founders James Krellenstein and Nick Faust shouted these words at Centers for Disease Control and Prevention (CDC) Director Robert Redfield, M.D., at AIDSWatch in Washington, D.C., on April 1, it was like they planned it all along.

Published
25 April 2019
From
The Body
Harm reduction
New “Generic” Naloxone: Expect More Big-Pharma Sleight of Hand

It’s been less than two weeks since the US Department of Justice joined a string of lawsuits against Indivior—the maker of the drug Suboxone, which is used to treat opioid use disorder— alleging the company engaged in a fraudulent patent-hopping scheme designed to prevent cheaper generic versions of the drug (a combination of buprenorphine and naloxone) from hitting market. Now the Food and Drug Administration has set the stage for yet another legal battle over lifesaving medication—and if history is a guide, profits are likely to be prioritized over people.

Published
25 April 2019
From
Filter
Pharmaceutical industry
US: The Justice Department Is Looking Into Gilead’s PrEP Profits

The Justice Department will investigate whether drug manufacturer Gilead violated the terms of the federal government’s patent on Truvada as pre-exposure prophylaxis, according to the Washington Post.

Published
25 April 2019
From
Out
Pharmaceutical industry
HIV drugmakers ViiV, Gilead top 2018 pharma reputation survey

Viiv, Gilead and Janssen led among global pharma companies in PatientView's annual reputation survey of patient groups.

Published
23 April 2019
From
FiercePharma
← Prev1...34567...117Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.